Peter de Nully Brown

Medicine & Life Sciences

1. Lymphoma, Large B-Cell, Diffuse 100%
2. Lymphoma 76%
3. Survival 35%
4. Hodgkin Disease 34%
5. Rituximab 30%
6. Mantle-Cell Lymphoma 29%
7. Denmark 28%
8. Drug Therapy 27%
9. Progression-Free Survival 25%
10. Recurrence 22%
11. Population 22%
12. Stem Cell Transplantation 21%
13. Peripheral T-Cell Lymphoma 21%
14. Follicular Lymphoma 20%
15. Registries 20%
16. Cohort Studies 20%
17. Non-Hodgkin's Lymphoma 19%
18. Positron Emission Tomography Computed Tomography 18%
19. Therapeutics 16%
20. B-Cell Lymphoma 14%
21. Survivors 12%
22. Confidence Intervals 11%
23. Radiotherapy 11%
24. Central Nervous System 11%
25. Neoplasms 10%
26. Databases 9%
27. Etoposide 9%
28. B-Cell Chronic Lymphocytic Leukemia 8%
29. Methylation 8%
30. Cell-Free Nucleic Acids 7%
31. Human papillomavirus 6 7%
32. Fluorodeoxyglucose F18 7%
33. Febrile Neutropenia 6%
34. Mutation 6%
35. Radiation 6%
36. Return to Work 6%
37. Vincristine 6%
38. Papillomavirus Vaccines 6%
39. L-Lactate Dehydrogenase 6%
40. MicroRNAs 6%
41. Cyclophosphamide 5%
42. Paranasal Sinuses 5%
43. Multivariate Analysis 5%
44. T-Cell Lymphoma 5%
45. Mortality 5%
46. R-CHOP protocol 5%
47. Multicenter Studies 5%
48. Thrombocytopenia 5%
49. Doxorubicin 5%
50. Genitalia 5%